Integrated analysis of tRNA-derived small RNAs in proliferative human aortic smooth muscle cells

Jian-Zhi Zhao¹,2†, Qi-Yao Li³†, Jia-Jie Lin¹†, Li-Yun Yang¹, Mei-Yang Du¹, Yu Wang¹, Ke-Xin Liu¹, Ze-An Jiang¹, Huan-Huan Li¹, Si-Fan Wang¹, Bo Sun¹, Shi-Qing Mu¹, Bin Li¹, Kun Liu¹, Miao Gong¹ and Shao-Guang Sun¹*

Abstract

Background: Abnormal proliferation of vascular smooth muscle cells (VSMCs) contributes to vascular remodeling diseases. Recently, it has been discovered that tRNA-derived small RNAs (tsRNAs), a new type of noncoding RNAs, are related to the proliferation and migration of VSMCs. tsRNAs regulate target gene expression through miRNA-like functions. This study aims to explore the potential of tsRNAs in human aortic smooth muscle cell (HASMC) proliferation.

Methods: High-throughput sequencing was performed to analyze the tsRNA expression profile of proliferative and quiescent HASMCs. Quantitative real-time polymerase chain reaction (qRT-PCR) was performed to validate the sequence results and subcellular distribution of AS-tDR-001370, AS-tDR-000067, AS-tDR-009512, and AS-tDR-000076. Based on the microRNA-like functions of tsRNAs, we predicted target promoters and mRNAs and constructed tsRNA–promoter and tsRNA–mRNA interaction networks. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses were performed to reveal the function of target genes. EdU incorporation assay, Western blot, and dual-luciferase reporter gene assay were utilized to detect the effects of tsRNAs on HASMC proliferation.

Results: Compared with quiescent HASMCs, there were 1838 differentially expressed tsRNAs in proliferative HASMCs, including 887 with increased expression (fold change > 2, p < 0.05) and 951 with decreased expression (fold change < ½, p < 0.05). AS-tDR-001370, AS-tDR-000067, AS-tDR-009512, and AS-tDR-000076 were increased in proliferative HASMCs and were mainly located in the nucleus. Bioinformatics analysis suggested that the four tsRNAs involved a variety of GO terms and pathways related to VSMC proliferation. AS-tDR-000067 promoted HASMC proliferation by suppressing p53 transcription in a promoter-targeted manner. AS-tDR-000076 accelerated HASMC proliferation by attenuating mitofusin 2 (MFN2) levels in a 3′-untranslated region (UTR)-targeted manner.

Conclusions: During HASMC proliferation, the expression levels of many tsRNAs are altered. AS-tDR-000067 and AS-tDR-000076 act as new factors promoting VSMC proliferation.

Keywords: tsRNA, VSMC, proliferation, p53, MFN2

© The Author(s) 2022. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/
Background
The death toll of cardiovascular diseases increases year by year, among which ischemic heart disease and cerebrovascular disease account for more than 80% of deaths [1]. Vascular smooth muscle cells (VSMCs), one of the cell types in blood vessels, mainly contract and relax to maintain blood pressure and flow [2]. Abnormal proliferation of VSMCs is a critical process in the pathogenesis of numerous vascular remodeling diseases, such as atherosclerosis [3], hypertension [4], vascular stenosis [5], and diabetic vascular complications [6]. Therefore, exploration of VSMC proliferation can contribute to the early diagnosis and treatment of pathological vascular conditions.

With the development of deep sequencing technology, tsRNAs, a new class of small noncoding RNAs derived from tRNAs, have been discovered in various organisms [7]. Interestingly, the roles of tsRNAs in mediating cardiovascular diseases by regulating VSMC proliferation have been gradually revealed recently [8–10]. For example, tRF^GlnCTG and tRF-Gly-GCC promote VSMC proliferation [8, 9], whereas 5′-tiRNA-Cys-GCA inhibits VSMC proliferation, migration, and dedifferentiation by reducing the levels of its target gene signal transducer and activator of transcription 4 (STAT4) [10]. However, the actual repertoire of tsRNAs affecting VSMC proliferation remains unclear.

This study aims to explore the roles of tsRNAs in VSMC proliferation. AS-tDR-000067 (tRFdb_ID: 3003a) targeted the promoter of p53 gene, and AS-tDR-000067 suppression inhibited HASMC proliferation by augmenting p53 levels. AS-tDR-000076 (tRFdb_ID: 3008a) targeted the 3′-UTR of MFN2 mRNA, and AS-tDR-000076 silencing limited HASMC proliferation by enhancing MFN2 levels. This study innovatively documents meaningful tsRNAs associated with HASMC proliferation and highlights AS-tDR-000067 and AS-tDR-000076 as promising factors that promote VSMC proliferation.

Methods
Cell culture
Proliferative HASMCs (ScienCell, CA, USA) were induced by smooth muscle cell medium (SMCM, ScienCell) containing 2% fetal bovine serum (FBS, ScienCell), 1% 100× smooth muscle cell growth supplement (SMCGS, ScienCell), and 1% 100× penicillin/streptomycin solution (ScienCell). Quiescent HASMCs were stimulated by FBS and SMCGS starvation for 24 h. Cells were cultured at 37 °C in an incubator containing 5% CO₂.

tsRNA-seq library preparation and sequencing
To screen tsRNAs related to HASMC proliferation, we performed high-throughput RNA sequencing of three sets of proliferative and quiescent HASMCs. Total RNA of proliferative and quiescent HASMCs was extracted using an RNA simple total RNA kit (TIANGEN, Beijing, China). Total RNA samples were pretreated to eliminate the interference of RNA modification in the construction of small RNA-seq libraries: (1) 3-aminooacyl (charged) was deacylated to 3′-OH for 3′ adaptor ligation; (2) 3′-cP (2′,3′-cyclic phosphate) was removed to 3′-OH for 3′ adaptor ligation; (3) 5′-OH (hydroxyl group) was phosphorylated to 5′-P for 5′-adaptor ligation; (4) m1A and m3C were demethylated.
for effective reverse transcription. Subsequently, tsRNA-seq libraries were constructed using a commercial kit for tsRNA sequencing library preparation (Illumina, CA, USA). The kit includes 3′-adapter and 5′-adapter ligation, complementary DNA (cDNA) synthesis, and library PCR amplification. PCR-amplified fragments with a size of 135–160 bp (corresponding to the size range of 15–40 nt small RNA) were selected as tsRNA-seq libraries. Finally, the prepared tsRNA-seq libraries were quantified using an Agilent 2100 Bioanalyzer (Agilent Technologies, CA, USA) and then sequenced using an Illumina NextSeq 500 (Illumina). Sequencing was performed by AKsomics (Shanghai, China). The tsRNA nomenclature used in this paper is derived from AKsomics, where AS indicates the abbreviation of AKsomics, tDR stands for tRNA-derived small RNA, and the number represents the order in which the tsRNA was found during sequencing. In addition, in our sequencing data, we also present the tRFdb_IDs of tsRNAs documented in the tRFdb database [11].

Sequencing data analysis
Image analysis and base calling were performed by Solexa pipeline v1.8 (Off-Line Base Caller software, v1.8). Valid sequences were preserved by alignment statistical analysis for subsequent tsRNA expression profile analysis and differential expression analysis. Sequencing quality was tested by FastQC software, and NovoAlign software (v2.07.11) was applied to align the trimmed reads (with 5′, 3′-adaptor bases removed) with the mature tRNA and pre-tRNA sequences of GtRNAdbb: Genomic tRNA Database (http://gtrnadb.ucsc.edu/). Remaining reads were aligned to the transcriptome including mRNA/rRNA/snRNA/piRNA/snoRNA/miRNA biotypes. The expression profile and differentially expressed tsRNAs (DEtsRNAs) were calculated based on standardized transcripts per million (TPM). DEtsRNAs can be obtained through GEO series accession number GSE164540 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE164540).

Quantitative real-time polymerase chain reaction (qRT-PCR)
Total small RNAs (smRNAs) of proliferative and quiescent HASMCs were isolated using a MiRcute miRNA Isolation Kit (TIANGEN). The quantity and integrity of total smRNAs were measured using NanoDrop ND-1000 (Thermo Fisher Science, Massachusetts, USA) and 1% agarose gel electrophoresis. Total smRNAs were reverse-transcribed using a MiRcute Plus miRNA First-Strand cDNA Kit (TIANGEN). qRT-PCR was performed using SYBR Green analysis in the miRcute Plus miRNA qPCR Kit (TIANGEN). The reaction conditions for all samples were initial denaturation at 95 °C for 10 min, followed by 40 cycles of heat denaturation at 95 °C for 10 s, annealing at 60 °C for 20 s, and extension at 72 °C for 10 s. All samples were normalized using U6 as internal control, and the $2^{-\Delta\Delta Ct}$ method was applied to calculate the fold change of expression of tsRNAs. The primers are presented in Additional file 1. The experiment was repeated three times for each gene.

Nuclear and cytoplasmic RNA detection
Nuclear and cytoplasmic components of proliferative HASMCs were isolated using a Nuclear/Cytosol Fractionation Kit (BioVision, CA, USA) following the manufacturer's
instructions. Extraction, quantification, and integrity detection of smRNAs were consistent with the above. The reaction conditions for qRT-PCR were in keeping with the above. GAPDH and U6 were applied as positive controls for the cytoplasm and nucleus, respectively. The primers are listed in Additional file 1. The experiment was repeated three times.

Construction of tsRNA–promoter interaction networks
Based on the seed region (tsRNA nucleotides 2–8), downstream target promoters of four DEtsRNAs (AS-tDR-001370, AS-tDR-000067, AS-tDR-009512, and AS-tDR-000076) were predicted by RNAhybrid [12] and MiRanda [13]. To further screen HASMC proliferation-related genes in a promoter-targeting manner, Venn analysis was performed between predicted genes containing target promoters and differentially expressed mRNAs (DEmRNAs) in proliferative HASMCs (GSE77279) (fold change > 2 or < ½, \( p < 0.05 \)) [14]. Target genes enriched in GO terms or pathways related to VSMC proliferation were selected to construct the tsRNA–promoter interaction networks using Cytoscape_v3.7.1. All target genes containing target promoters are listed in Additional file 2.

Construction of tsRNA–mRNA interaction networks
Based on the seed sequence targeting the 3′-untranslated region (UTR) of mRNA, downstream target genes of four DEtsRNAs (AS-tDR-001370, AS-tDR-000067, AS-tDR-009512, and AS-tDR-000076) were predicted by TargetScan [15] and MiRanda [13]. Venn analysis between predicted target genes and DEmRNAs in the proliferative HASMCs (GSE77279) (fold change < 2/3, \( p < 0.05 \)) [14] was performed to obtain target DEmRNAs. Target genes enriched in GO terms or pathways related to VSMC proliferation were selected to construct the tsRNA–mRNA interaction networks utilizing Cytoscape_v3.7.1. In addition, based on the seed sequence targeting the 3′-UTR of mRNAs, downstream target genes of AS-tDR-013295 and AS-tDR-001583 were predicted by TargetScan [15]. Venn analysis between predicted target genes and DEmRNAs in the proliferative HASMCs (GSE77279) (fold change > 1.5, \( p < 0.05 \)) [14] was performed to obtain target DEmRNAs. The tsRNA–mRNA interaction networks were constructed utilizing Cytoscape_v3.7.1. All target DEmRNAs are listed in Additional file 3.

GO and pathway analyses
For the GO and pathway analyses of target DEmRNAs and HASMC proliferation-related genes containing target promoters, we explored the potential function of AS-tDR-001370, AS-tDR-000067, AS-tDR-009512, and AS-tDR-000076 on HASMC proliferation using the DAVID database [16].

Antisense oligonucleotide transfection
Antisense oligonucleotides (ASOs) of AS-tDR-000067, AS-tDR-000076, and negative control (ASO-Control) were designed and synthesized by GENEWIZ (Beijing, China). According to the instructions, Lipofectamine 3000 (Invitrogen, CA, USA) was used to transfect ASO-Control, ASO-AS-tDR-000067, or ASO-AS-tDR-000076 into HASMCs. After 7 h, the transfection medium was replaced with fresh SMCM containing 2% FBS, 1%
100 × SMCGS, and 1% 100 × penicillin/streptomycin solution and cultured to the appropriate time point. Sequences of related ASOs are listed in Additional file 4.

**Western blot analysis**

Total protein in HASMCs was extracted using radioimmunoprecipitation assay (RIPA) buffer (Solarbio, Beijing, China) and 1 mM phenylmethylsulfonyl fluoride (PMSF; Solarbio). Sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE) was performed to separate equal amounts of proteins and transfer them onto the polyvinylidene fluoride (PVDF) membrane (Merck, Darmstadt, Germany). After blocking with 5% skimmed milk at 37 °C for 2 h, the membranes were incubated overnight at 4 °C with the following specific primary antibodies: p53 (1:1000; Wanleibio, Shenyang, China), mitofusin 2 (MFN2, 1:500; Abcam), α-smooth muscle actin (α-SMA, 1:500; Wanleibio), proliferating cell nuclear antigen (PCNA, 1:1000, Proteintech, Wuhan, China), β-actin (1: 1,000, Proteintech), and glyceraldehyde-3-phosphate dehydrogenase (GAPDH, 1:1000; Wanleibio). After washing three times in Tris-buffered saline within Tween 20 (TBST) for 5 min, the membranes were incubated in goat anti-rabbit secondary antibody (dilution at 1:20,000, Sino Biological) for 1 h at room temperature. A ChemiDoc™ MP Imaging System (BIO-RAD, CA, USA) was employed to visualize the protein signals and quantify band strength. The experiment was repeated at least three times.

**Cell proliferation analysis**

After the corresponding treatment of HASMCs, a 5-ethynyl-2′-deoxyuridine (EdU) incorporation assay was performed according to the instructions of the BeyoClick™ EdU Cell Proliferation Kit and Alexa Fluor 594 (Beyotime, Shanghai, China). EdU-positive cells were observed by fluorescence microscope (Olympus IX71, Tokyo, Japan). The experiment was repeated three times.

**Dual-luciferase reporter gene assay**

Dual-luciferase reporter assays were performed to evaluate the direct binding of AS-tDR-000067 to the p53 promoter, as well as AS-tDR-000076 to the MFN2 3′-UTR. Using GPtransfect-Mate (GenePharma, Shanghai, China), luciferase reporter gene vector (psi-CHECKTM-2 Vector, Promega, USA) containing the wild-type (WT) p53 promoter was cotransfected into 293A cells with AS-tDR-000067 mimic or AS-tDR-000067 mutant (GenePharma). Similarly, the vector containing the WT MFN2 3′-UTR was cotransfected with AS-tDR-000076 mimic or AS-tDR-000076 mutant (GenePharma). After 24 h, the Dual-Luciferase® Reporter Assay System (Promega) was performed based on the manufacturer’s instructions. For each analysis, the Renilla luciferase signal was normalized to the firefly luciferase signal. Sequences of tsRNA mimics and tsRNA mutant are listed in Additional file 5. The experiment was repeated three times.

**Statistical analysis**

All data are from at least three independent experiments, expressed as mean ± standard deviation (SD). Student’s t-test was performed to compare the differences between two groups. p < 0.05 was considered statistically significant.
**Results**

**Expression profile analysis and qRT-PCR detection of tsRNAs**

Compared with quiescent HASMCs, PCNA levels were increased together with decreased α-SMA levels, and cell proliferation rate was significantly augmented in proliferative HASMCs (Additional file 6), suggesting successful induction of two cell phenotypes for screening HASMC proliferation-related tsRNAs. Using RNA sequencing, we screened 3891 tsRNAs to explore their expression profiles in two HASMC phenotypes. The scatter plot in Fig. 1A, volcano plot in Fig. 1B, and hierarchical clustering in Fig. 1C illustrate that, in contrast to quiescent HASMCs, proliferative HASMCs possessed 887 increased DETsRNAs and 951 decreased DETsRNAs (fold change > 2 or < ½, \( p < 0.05 \)). According to the fold change and expression abundance, four DETsRNAs (AS-tDR-001370, AS-tDR-000067, AS-tDR-009512, and AS-tDR-000076) were selected for qRT-PCR detection. Consistent with the sequencing, AS-tDR-001370, AS-tDR-000067, AS-tDR-009512, and AS-tDR-000076 were higher in proliferative HASMCs (Fig. 1D). Nuclear/cytoplasmic RNA detection revealed that the four DETsRNAs were predominantly localized in the nucleus of HASMCs (Fig. 1E).
Construction of tsRNA–promoter interaction networks
The functions of tsRNAs binding to Argonaute (AGO) proteins are similar to miRNAs [17]. The binding of nuclear miRNAs to promoters leads to activation [18] or silencing [19] of the transcription of target genes. We thus speculated that tsRNAs are similar to miRNAs and play regulatory roles by targeting promoters. Four DEtsRNAs (AS-tDR-001370, AS-tDR-000067, AS-tDR-009512, and AS-tDR-000076) were selected to construct tsRNA–promoter interaction networks (Fig. 2).

Functional annotation of genes containing target promoters
GO and pathway analyses of genes containing target promoters were performed to explore the potential of AS-tDR-001370, AS-tDR-000067, AS-tDR-009512, and AS-tDR-000076 in HASMC proliferation using the DAVID database [15]. GO analysis revealed that the four DEtsRNAs were enriched in histone deacetylase binding (ontology: molecular function, GO: 0042826), peptidyl-threonine phosphorylation (ontology: biological process, GO:0018107), hippo signaling (ontology: biological process, GO: 0035329), regulation of stem cell population maintenance (ontology: biological process, GO: 2000036), regulation of cell cycle arrest (ontology: biological process, GO: 0071156),
and negative regulation of cell growth (ontology: biological process, GO: 0030308) (Additional file 7). In addition, pathway analysis revealed that the four DEtsRNAs were enriched in mitogen-activated protein kinase (MAPK) signaling pathway (hsa04010), p53 signaling pathway (hsa04115), vascular smooth muscle contraction (hsa04270), Wnt signaling pathway (hsa04310), and other cell proliferation-related pathways (Additional file 7).

**Construction of tsRNA–mRNA interaction networks**

Similar to miRNAs, tsRNAs inhibit mRNA expression in a sequence-dependent manner by binding to AGO [20]. Four DEtsRNAs (AS-tDR-001370, AS-tDR-000067, AS-tDR-009512, and AS-tDR-000076) were selected to construct tsRNA–mRNA interaction networks (Fig. 3).

**Functional annotation of target DEmRNAs**

GO and pathway analyses of target DEmRNAs were performed to explore the potential of AS-tDR-001370, AS-tDR-000067, AS-tDR-009512, and AS-tDR-000076 in HASMC proliferation. GO analysis revealed that the four DEtsRNAs were involved in regulation
of complement activation (ontology: biological process, GO: 0030449), actin cytoskeleton organization (ontology: biological process, GO: 0030036), regulation of tumor necrosis factor-mediated signaling pathway (ontology: biological process, GO: 0010803), negative regulation of cell migration (ontology: biological process, GO: 0030336), and negative regulation of smooth muscle cell proliferation (ontology: biological process, GO: 0048662) (Additional file 8). In addition, pathway analysis revealed that the four DEtsRNAs were enriched in Notch signaling pathway (hsa04330), adenosine monophosphate-activated protein kinase (AMPK) signaling pathway (hsa04152), vascular endothelial growth factor (VEGF) signaling pathway (hsa04370), RNA polymerase (hsa03020), and arachidonic acid metabolism (hsa00590) (Additional file 8).

AS-tDR-000067 suppression inhibits HASMC proliferation by elevating p53 levels
According to RNA-seq and qRT-PCR, AS-tDR-000067 was increased in proliferative HASMCs (Fig. 1D). Antisense oligonucleotide (ASO) specifically suppressed approximately 60% of AS-tDR-000067 expression in HASMCs (Additional file 9). AS-tDR-000067 suppression inhibited HASMC proliferation by 80%, as confirmed by the EdU incorporation assay (Fig. 4A, B). Interestingly, a crucial anti-oncogene, p53 [21], stood out in the AS-tDR-000067-promoter interaction network (Fig. 2B). AS-tDR-000067 inhibition enhanced p53 protein levels in HASMCs (Fig. 4C). Through RNAhybrid [12], we found a potential binding site between AS-tDR-000067 and p53 promoter (Fig. 4D). Dual-luciferase reporter gene assay revealed that AS-tDR-000067 mimic inhibited the fluorescence activity of p53-WT plasmid (Fig. 4E), indicating that the promoter of p53 was a target of AS-tDR-000067. These findings suggest that AS-tDR-000067 promotes HASMC proliferation, at least in part, by inhibiting p53 transcription in a promoter-targeted manner.

AS-tDR-000076 silencing restrains HASMC proliferation by augmenting MFN2 levels
In the light of the RNA-seq and qRT-PCR results, AS-tDR-000076 was increased in proliferative HASMCs (Fig. 1D). Moreover, GO analysis showed that target DEmRNAs of AS-tDR-000076 were enriched in negative regulation of smooth muscle cell proliferation (ontology: biological process, GO: 0048662) (Additional file 8). These two clues suggest that AS-tDR-000076 might be a regulator of HASMC proliferation. ASO specifically restrained approximately 60% of AS-tDR-000076 expression in HASMCs (Additional file 9). AS-tDR-000076 silencing resulted in a reduction of up to 80% in EdU-positive cells (Fig. 5A, B). Intriguingly, MFN2, a crucial VSMC proliferation inhibitor confirmed by our group [22] and others [23–26], is a target gene of AS-tDR-000076 (Fig. 3D). AS-tDR-000076 silencing promoted MFN2 protein levels in HASMCs (Fig. 5C). Utilizing RNAhybrid [12], we found a possible binding site between AS-tDR-000076 and MFN2 3′-UTR (Fig. 5D). Dual-luciferase reporter gene assay revealed that AS-tDR-000076 mimic decreased the fluorescence activity of MFN2-WT plasmid (Fig. 5E), manifesting that the 3′-UTR of MFN2 was a target of AS-tDR-000076. These findings elucidate that AS-tDR-000076 promotes HASMC proliferation, at least in part, by restricting MFN2 levels in a 3′-UTR-targeted manner.
Discussion

tsRNAs, a new type of noncoding RNAs derived from tRNAs, are receiving increasing attention. tsRNAs are abundant, evolutionarily conserved, and widely distributed, suggesting that they are not the by-products of tRNA production or degradation, and may be involved in organism regulation [27–29]. There are two hot spots in the mechanism of tsRNAs; one is the interaction with proteins [30, 31], and the other is the miRNA-like function that inhibits target gene expression [32]. Through these mechanisms, tsRNAs regulate cell proliferation [33], migration [34], apoptosis [35], and other biological processes [36]. At present, studies on tsRNAs are mainly focused on revealing their roles in cancer [37].

Intriguingly, the mystery that tsRNAs are involved in cardiovascular disease by regulating VSMC proliferation has been gradually resolved [8–10]. tRF^{GlnCTG}, which is highly increased in injured rat common carotid arteries, promotes rat VSMC proliferation by inhibiting Fas cell surface death receptor (FAS) levels in a 3′-UTR-targeted manner [8]. tRF-Gly-GCC is increased in patients with atherosclerosis and promotes VSMC
proliferation [9]. 5′-tiRNA-Cys-GCA, which is decreased in human and mouse aortic dissection, inhibits VSMC proliferation by reducing STAT4 levels in a 3′-UTR-targeted manner [10]. However, understanding the regulation of VSMC proliferation by tsRNAs is still in its infancy.

Here, we identified 1838 DEtsRNAs between proliferative and quiescent HASMCs using RNA-seq (Fig. 1A–C). Four DEtsRNAs (AS-tDR-001370, AS-tDR-000067, AS-tDR-009512, and AS-tDR-000076) were increased in proliferative HASMCs (Fig. 1D) and mainly located in the nucleus of HASMCs (Fig. 1E). It is worth noting that the regulatory role of tsRNAs in the nucleus has not been well explored, including in VSMC proliferation. Given that miRNAs activate or restrain the transcriptional process in the nucleus by targeting promoters [18, 19], we speculated that tsRNAs might have the same function. We predicted target promoters of the four DEtsRNAs and constructed tsRNA–promoter interaction networks (Fig. 2). Four gene sets containing target promoters were enriched in some VSMC proliferation-related GO terms and pathways (Additional file 7). Analysis of tsRNA–promoter interaction networks

Fig. 5 AS-tDR-000076 silencing restrains HASMC proliferation by augmenting MFN2 levels. A EdU incorporation assay of HASMCs transfected with ASO-Control or ASO-AS-tDR-000076. Blue fluorescence (Hoechst 33342) indicates cell nuclei, while red fluorescence (EdU) represents HASMCs with DNA synthesis. Scale bar 10 µm; B Relative EdU-positive HASMCs. Data shown as the ratio of EdU-positive HASMCs to total ones. Data expressed as mean ± SD of at least three independent experiments, ***p < 0.001 versus ASO-Control group; C Western blot analysis of MFN2 in HASMCs transfected with ASO-Control or ASO-AS-tDR-000076, with GAPDH as control. Data shown as mean ± SD of three independent experiments, **p < 0.01 versus ASO-Control group; D Schematic of binding sites of AS-tDR-000076 to MFN2 3′-UTR; E Confirmation of MFN2 3′-UTR as a target of AS-tDR-000076 employing the dual-luciferase reporter gene assay. Data shown as mean ± SD of at least three independent experiments, *p < 0.05.
indicated that AS-tDR-001370 might target the promoters of cyclin D1 (CCND1) and sprouty RTK signaling antagonist 2 (SPRY2) (Fig. 2A). CCND1 has been confirmed to promote VSMC proliferation [38]. SPRY2 reduces neointimal growth after vascular injury by inhibiting VSMC proliferation and migration [39]. Therefore, AS-tDR-001370 might promote HASMC proliferation by activating CCND1 transcription but inhibiting SPRY2 transcription. Reticulon 4 (RTN4), which inhibits VSMC proliferation and migration [40], contained the target promoter of AS-tDR-009512 (Fig. 2C). Hence, AS-tDR-009512 might facilitate HASMC proliferation by suppressing RTN4 transcription. AS-tDR-000076 was likely to target the promoters of CCND1 and transforming growth factor beta 1 (TGFβ1) (Fig. 2D). TGFβ1 inhibits VSMC proliferation and promotes VSMC apoptosis [41]. Accordingly, AS-tDR-000076 might accelerate HASMC proliferation by motivating CCND1 transcription but restricting TGFβ1 transcription.

Excitingly, we found that the promoter of p53 might be targeted by AS-tDR-000067 (Fig. 2B). p53 is a crucial tumor suppressor gene, and the transcription factor it encodes is essential for the cell cycle and apoptosis [21]. A large number of studies have confirmed that p53 prevents atherosclerosis [42], hypertension [43], vascular stenosis [44], and other vascular remodeling diseases by inhibiting VSMC proliferation, invasion, and migration and inducing VSMC apoptosis. In this study, we revealed that AS-tDR-000067 suppression inhibited HASMC proliferation (Fig. 4A, B) accompanied by augmented p53 levels (Fig. 4C), and further elucidated that the promoter of p53 is a target of AS-tDR-000067 (Fig. 4D, E). Taken together, we document that AS-tDR-000067 promotes HASMC proliferation, at least in part, via inhibiting transcription of p53 in a promoter-targeted manner. However, the mechanism of AS-tDR-000067 translocation into the nucleus is not explored in this work and requires further verification.

In addition, four target DEmRNA sets were also enriched in some VSMC proliferation-related GO terms and pathways (Additional file 8). Investigation of tsRNA–mRNA interaction networks revealed that AS-tDR-009512 might target tropomyosin 1 (TPM1) and transmembrane protein with EGF-like and two follistatin-like domains 2 (TMEFF2) (Fig. 3C). miR-21 promotes VSMC proliferation and migration by targeting and reducing TPM1 [45, 46]. TMEFF2 blocks proliferation of pancreatic cancer cells by inhibiting phosphorylation of the MAPK signaling pathway [47], and the MAPK signaling pathway is highly correlated with VSMC proliferation [48], which hints that TMEFF2 might inhibit VSMC proliferation via the MAPK signaling pathway. Hence, AS-tDR-009512 was likely to promote HASMC proliferation by targeting and suppressing TPM1 and TMEFF2. AS-tDR-000076 was likelihood to target TMEFF2 and splicing factor 1 (SF1) (Fig. 3D). SF1 has been confirmed to inhibit VSMC proliferation [49]. Therefore, AS-tDR-000076 might accelerate HASMC proliferation by silencing SF1 and TMEFF2.

In particular, MFN2 was also a potential target gene of AS-tDR-000076 (Fig. 3D). MFN2 has been verified to restrain VSMC proliferation by our group [22] and others [23–26]. In this study, we uncovered that AS-tDR-000076 silencing restrained HASMC proliferation (Fig. 5A, B) combined with increased MFN2 levels (Fig. 5C), and further clarified that MFN2 is a target of AS-tDR-000076 (Fig. 5D, E). Our data
confirm that AS-tDR-000076 accelerates HASMC proliferation, at least in part, via suppressing MFN2 levels in a 3'–UTR-targeted manner.

In our sequencing data, AS-tDR-013295 and AS-tDR-001583 were outstandingly decreased in proliferative compared with quiescent HASMCs. To explore the biological functions of AS-tDR-013295 and AS-tDR-001583, we predicted their target DEmRNAs and constructed tsRNA–mRNA interaction networks (Additional file 10). From the networks, we found that AS-tDR-013295 might target myristoylated alanine-rich protein kinase C substrate (MARCKS) (Additional file 10). MARCKS silencing attenuates VSMC migration and proliferation by increasing cyclin-dependent kinase inhibitor p27 [50]. In addition, AS-tDR-001583 might bind to the myeloid-associated differentiation marker (MYADM) (Additional file 10). MYADM-triggered VSMC proliferation plays a vital role in the development of pulmonary arterial hypertension vascular remodeling via a Krüppel-like factor 4 (KLF4) nuclear export-dependent mechanism, leading to decreased cyclin-dependent kinase inhibitor 1A (p21) levels [51]. Therefore, we speculated that AS-tDR-013295 and AS-tDR-001583 might inhibit VSMC proliferation by suppressing the levels of VSMC proliferation promoters MARCKS and MYADM, respectively. However, this hypothesis needs to be investigated in the future.

Conclusions
We reveal for the first time a significant difference in tsRNA expression profiles between proliferative and quiescent HASMCs. Furthermore, our results confirm that AS-tDR-000067 promotes HASMC proliferation, at least in part, via suppressing p53 transcription in a promoter-targeted manner. And AS-tDR-000076 accelerates HASMC proliferation, to some extent, via attenuating MFN2 levels in a 3'–UTR-targeted manner. Our results provide clues regarding the regulation of VSMC proliferation by tsRNAs and highlight AS-tDR-000067 and AS-tDR-000076 as significant factors enhancing VSMC proliferation.

Abbreviations
AGO Argonaute
AMPK Adenosine monophosphate-activated protein kinase
ASOs Antisense oligonucleotides
CCND1 Cyclin D1
DEmRNAs Differentially expressed mRNAs
DEtsRNAs Differentially expressed tsRNAs
EdU 5-Ethynyl-2'-deoxyuridine
FAS Fas cell surface death receptor
GAPDH Glyceraldehyde-3-phosphate dehydrogenase
GO Gene Ontology
HASMC Human aortic smooth muscle cell
KEGG Kyoto Encyclopedia of Genes and Genomes
MARCKS Myristoylated alanine-rich protein kinase C substrate
MAPK Mitogen-activated protein kinase
MFN2 Mitofusin 2
MYADM Myeloid-associated differentiation marker
PCNA Proliferating cell nuclear antigen
PMSF Phenylmethylsulfonyl fluoride
qRT-PCR Quantitative real-time polymerase chain reaction
RTN4 Reticulin 4
RIPA Radioimmunoprecipitation assay
SF1 Splicing factor 1
SDS-PAGE Sodium dodecyl sulfate-polyacrylamide gel electrophoresis
smRNAs Small RNAs
STAT4 Signal transducer and activator of transcription 4
SPRY2  Sprouty RTK signaling antagonist 2  
tsRNAs  tRNA-derived small RNAs  
TPM1  Tropomyosin 1  
TMEFF2  Transmembrane protein with EGF-like and two follistatin-like domains 2  
TGFβ1  Transforming growth factor beta 1  
UTR  Untranslated region  
VEGF  Vascular endothelial growth factor  
VSMCs  Vascular smooth muscle cells  
α-SMA  α-smooth muscle actin

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s11658-022-00346-4.

Additional file 1: Table S1. Primers for qRT-PCR.
Additional file 2: Table S2. The gene list containing the target promoters of tsRNAs.
Additional file 4: Table S4. Sequences of ASOs.
Additional file 5: Table S5. Sequences of tsRNA mimics and tsRNA-mutant.

Additional file 6: Figure S1. Successful induction of proliferative and quiescent HASMCs. A, B Western blot analysis of α-SMA and PCNA between proliferative and quiescent HASMCs, with β-actin as control. Data shown as mean ± SD of four independent experiments, *p < 0.05 versus quiescent HASMCs. C EdU incorporation assay of differences in DNA synthesis between proliferative and quiescent HASMCs. Blue fluorescence (Hoechst 33342) indicates cell nuclei, while red fluorescence (EdU) represents HASMCs with DNA synthesis. Scale bar 10 µm. D Relative EdU-positive HASMCs. Data expressed as ratio of EdU-positive HASMCs to total ones. Data shown as mean ± SD of at least three independent experiments, ****p < 0.0001 versus quiescent HASMCs.

Additional file 7: Figure S2. Functional annotation of genes containing target promoters. GO terms of genes containing target promoters of A AS-tDR-001370, C AS-tDR-000067, E AS-tDR-009512, and G AS-tDR-000076. Pathways of genes containing target promoters of B AS-tDR-001370, D AS-tDR-000067, F AS-tDR-009512, and H AS-tDR-000076.

Additional file 8: Figure S3. Functional annotation of target DEmRNAs. GO terms of target DEmRNAs of A AS-tDR-001370, C AS-tDR-000067, E AS-tDR-009512, and G AS-tDR-000076. Pathways of target DEmRNAs of B AS-tDR-001370, D AS-tDR-000067, F AS-tDR-009512, and H AS-tDR-000076.

Acknowledgements
We are grateful to Research Square for publishing a preprint version of this manuscript so that we can share our work early and gain feedback from the community. This preprint version is available at https://doi.org/10.21203/rs.3.rs-482321/v1.

Author contributions
SGS designed and supervised this study. JZZ, QYL, JJL, LY, MYD, HHL, BS, SFW, and BL performed the bioinformatics analysis. JZZ, QYL, JJL, LY, MYD, YW, KXL, ZAJ, SQM, KL, and MG performed the experiments. JZZ, QYL, and JJL wrote the manuscript. All authors have read and agreed to the published version of the manuscript. All authors read and approved the final manuscript.

Funding
This research was funded by the National Natural Science Foundation of China (grant nos. 82170439, 81670273, and 8120215 to SGS) and Natural Science Foundation of Hebei Province (grant nos. H2021206399 and H2019206150 to SGS).

Availability of data and materials
The datasets generated during the current study are available in the [GEO] repository at [https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE164540].
Declarations

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
The authors declare no competing interests.

Received: 17 February 2022   Accepted: 24 May 2022
Published online: 15 June 2022

References

1. Collaborators GBDCoD. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390:1151–210.
2. Owens GK, Kumar MS, Wamhoff BR. Molecular regulation of vascular smooth muscle cell differentiation in develop‑ment and disease. Physiol Rev. 2004;84:767–801.
3. Sun B, Cao Q, Meng M, Wang X. MicroRNA-186-5p serves as a diagnostic biomarker in atherosclerosis and regulates vascular smooth muscle cell proliferation and migration. Cell Mol Biol Lett. 2020;25:27.
4. Han Y, Liu Y, Yang C, Gao C, Guo X, Cheng J. LncRNA CASC2 inhibits hypoxia-induced pulmonary artery smooth muscle cell proliferation and migration by regulating the miR-222/ING5 axis. Cell Mol Biol Lett. 2020;25:21.
5. Jeong K, Kim JH, Murphy JM, Park H, Kim SJ, Rodriguez YAR, Kong H, Choi C, Guan JL, Taylor JM, Lincoln TM, Gerthoffer WT, Kim JS, Ahn EE, Schlaepfer DD, Lim SS. Nuclear focal adhesion kinase controls vascular smooth muscle cell proliferation and neointimal hyperplasia through GATA4-mediated cyclin D1 transcription. Circ Res. 2019;125:152–66.
6. Matsuoka T, Wada J, Hashimoto I, Zhang Y, Eguchi J, Ogawa N, Shikata K, Kanwar YS, Makino H. Gene delivery of Tim44 reduces mitochondrial superoxide production and ameliorates neointimal proliferation of injured carotid artery in diabetic rats. Diabetes. 2005;54:2882–90.
7. Lee YS, Shibata Y, Malhotra A, Dutta A. A novel class of small RNAs: tRNA-derived RNA fragments (tRFs). Genes Dev. 2009;23:2639–49.
8. Zhu XL, Shi Y, Wang J, Yu J, Guan YY, Deng JJ, Ji X, Ji X, Ji C, Zong T, Li X, Zhang Y, Zou Y, Yu T. Expression profiles and potential roles of transfer RNA-derived small RNAs in atherosclerosis. J Cell Mol Med. 2021;25:7052–65.
9. Zong T, Yang Y, Lin X, Jiang S, Zhao H, Liu M, Meng Y, Li Y, Zhao L, Tang G, Gong K, Wang Z, Yu T. S'-tRNA-Cys-GCA regulates VSMC proliferation and phenotypic transition by targeting STAT4 in aortic dissection. Mol Ther Nucleic Acids. 2021;26:295–306.
10. Kumar P, Mudunuri SB, Anaya J, Dutta A. tRFdb: a database for transfer RNA fragments. Nucleic Acids Res. 2015;43:D141–145.
11. Kruger J, Rehmsmeier M. RNAhybrid: microRNA target prediction easy, fast and flexible. Nucleic Acids Res. 2006;34:W451–454.
12. John B, Enright AJ, Aravin A, Tuschl T, Sander C, Marks DS. Human MicroRNA targets. PLoS Biol. 2004;2:e363.
13. Lin JJ, Chen W, Geng M, Xu X, Xu MY, Wang SF, Wang Y, Yu KX, Kong P, Liu B, Liu K, Li YM, Dong LH, Sun SG. Expression and functional analysis of lncRNAs involved in platelet-derived growth factor-BB-induced proliferation of human aortic smooth muscle cells. Front Cardiovasc Med. 2021;8:702718.
14. Agarwal V, Bell GW, Nam JW, Bartel DP. Predicting effective microRNA target sites in mammalian mRNAs. Elife. 2015;4:e05005.
15. da Huang W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4:44–57.
16. Kumar P, Anaya J, Mudunuri SB, Dutta A. Meta-analysis of tRNA-derived RNA fragments reveals that they are evolutionarily conserved and associate with AGO proteins to recognize specific RNA targets. BMC Biol. 2014;12:78.
17. Li H, Fan J, Zhao Y, Zhang X, Dai B, Zhan J, Yin Z, Nie X, Fu XD, Chen C, Wang DW. Nuclear miR-320 mediates diabetes-induced cardiac dysfunction by activating transcription of fatty acid metabolic genes to cause lipotoxicity in the heart. Circ Res. 2019;125:1106–20.
18. Di Mauro V, Crotto S, Colombo FS, Di Pasquale E, Catalucci D. Wnt signalling mediates miR-133a nuclear re-localization for the transcriptional control of Dmnt3b in cardiac cells. Sci Rep. 2019;9:9320.
19. Maute RL, Schneider C, Surnazin P, Holmes A, Calafano A, Basso K, Dalla-Favera R. tRNA-derived microRNA modulates proliferation and the DNA damage response and is down-regulated in B cell lymphoma. Proc Natl Acad Sci U S A. 2013;110:1404–9.
20. Muller PA, Vosden KH. Mutant p53 in cancer: new functions and therapeutic opportunities. Cancer Cell. 2014;25:304–17.
21. Zhang R, Han M, Zheng B, Li Y, Shu YN, Wen JK. Kruppel-like factor 4 interacts with p300 to activate mitofusin 2 gene expression induced by all-trans retinoic acid in VSMCs. Acta Pharmacol Sin. 2010;31:1293–302.
24. Lu Z, Li S, Zhao S, Fa X. Upregulated miR-17 regulates hypoxia-mediated human pulmonary artery smooth muscle cell proliferation and apoptosis by targeting mitofusin 2. Med Sci Monit. 2016;22:3301–8.
25. Feng S, Gao L, Zhang D, Tian X, Kong L, Shi H, Wu L, Huang Z, Du B, Liang C, Zhang Y, Yao R. MiR-93 regulates vascular smooth muscle cell proliferation, and neo-intimal formation through targeting Mfn2. Int J Biol Sci. 2019;15:2615–26.
26. Xu L, Hao H, Hsiao Y, Wei G, Li G, Ma P, Xu L, Ding N, Ma S, Chen AF, Jiang Y. Aberrant MEF2 transcription facilitates homocysteine-induced VSMCs proliferation via the increased binding of c-Myc to DNMT1 in atherosclerosis. J Cell Mol Med. 2019;23:4611–26.
27. Li F, Kaczor-Urbanowicz KE, Sun J, Meng B, Lo HC, Kim Y, Koyano K, Rao SL, Kang SY, Kim SM, Kim KM, Kim S, Chia D, Bellodi C. Pseudouridylation of tRNA-derived fragments steers translational control in stem cells. Cell. 2017;173:1204–12.e1226.
28. Godoy PM, Bhakta NR, Barczak AJ, Cakmak H, Fisher S, MacKenzie TC, Patel T, Price RW, Smith JF, Woodruff PG, Erle DJ. Large differences in small RNA composition between human biofluids. Cell Rep. 2018;25:1346–58.
29. Krishna S, Raghavan S, DasGupta R, Palakodeti D. tRNA-derived fragments (tRFs): establishing their turf in post-transcriptional gene regulation. Cell Mol Life Sci. 2021. https://doi.org/10.1007/s00018-020-03720-7.
30. Guzzi N, Ciesla M, Ngoc PCT, Lang S, Arora S, Dimitriou M, Pimkova K, Sommarin MNE, Munita R, Lubas M, Lim Y, Okuyama K, Sonje S, Karlsson G, Hansson J, Jonsson G, Lundh AH, Sigvardsson M, Hellstrom-Lindberg E, Hsieh AC. Large differences in small RNA composition between human biofluids. Cell Rep. 2018;25:1346–58.
31. Kim HK, Xu J, Chu K, Park H, Jang H, Li P, Valdmanis PN, Zhang QC, Kay MA. A tRNA-derived small rna regulates ribosomal protein S28 protein levels after translation initiation in humans and mice. Cell Rep. 2019;29:3816–24.e3814.
32. Martinez J, Choudry SG, Slotkin RD. tRNA-derived small RNAs target transposable element transcripts. Nucleic Acids Res. 2017;45:5142–52.
33. Huang B, Yang H, Cheng X, Wang D, Fu S, Shen W, Zhang Q, Zhang L, Yue Z, Li Y, Da Y, Yang Q, Li Z, Liu L, Qiao L, Kong Y, Yao Z, Zhao P, Li M, Zhang R. tRF/miR-1280 suppresses stem cell-like cells and metastasis in colorectal cancer. Cancer Res. 2017;77:3194–206.
34. Goodarzi H, Liu X, Nguyen HC, Zhang S, Fish L, Tavazoie SF. Endogenous tRNA-derived fragments suppress breast cancer progression via YBX1 displacement. Cell. 2015;161:790–802.
35. Saika M, Jobava R, Pansien M, Putnam A, Krokowski D, Gao XH, Guo Z, Hu Y, Jankowsky E, Feng Z, Hu GF, Pusztai-Carey M, Gorita M, Sepuni NB, Pan T, Hatzoglou M. Angiogenin-cleaved tRNA halves interact with cytochrome c, protecting cells from apoptosis during osmotic stress. Mol Cell Biol. 2014;34:2450–60.
36. Krishna S, Yim DG, Lakshmanan V, Tirumalai V, Koh JL, Park J, Cheong JK, Low JL, Lim ML, Sze SK, Shivaprakash P, Gulyani A, Raghavan S, Palakodeti D, DasGupta R. Dynamic expression of tRNA-derived small RNAs define cellular states. EMBO Rep. 2019;20:e47789.
37. Zhu L, Ge J, Li T, Shen Y, Guo J. tRNA-derived fragments and tRNA halves: the new players in cancers. Cancer Lett. 2019;452:31–7.
38. Xiao Q, Zhang F, Grassia G, Hu Y, Zhang Z, Xing Q, Yin X, Maddaluno M, Drung B, Schmidt B, Maffia P, Ialenti A, Mayr M, Xu Q, Ye S. Matrix metalloproteinase-8 promotes vascular smooth muscle cell proliferation and neo-intima formation. Arterioscler Thromb Vasc Biol. 2014;34:90–8.
39. Zhang C, Chaturvedi D, Jaggar L, Magnussen D, Lee JM, Patel TB. Regulation of vascular smooth muscle cell proliferation and migration by human sproty 2. Arterioscler Thromb Vasc Biol. 2005;25:533–8.
40. Chick HE, Nowrouzi A, Franza R, McDonald RA, Kane NW, Alba R, Delles C, Sesia WC, Schmidt M, Thrasher AJ, Baker AH. Integrase-deficient lentiviral vectors mediate efficient gene transfer to human vascular smooth muscle cells with minimal genotoxic risk. Hum Gene Ther. 2012;23:1247–57.
41. Liu W, Luo M, Zou L, Liu Y, Wang R, Tao H, Wu D, Zhang W, Luo Q, Zhao Y. uNK cell-derived TGF-beta1 regulates vascular smooth muscle cell proliferation and apoptosis by targeting mitofusin 2. Med Sci Monit. 2016;22:3301–8.
42. Wang M, Li W, Chang GQ, Ye CS, Ou S, Li X, Li Y, Cheang TY, Huang XL, Wang SM. MicroRNA-21 regulates vascular smooth muscle cell function via targeting tropomyosin 1 in atherosclerosis obliterans of lower extremities. Arterioscler Thromb Vasc Biol. 2011;31:2044–53.
43. Jia S, Ma WD, Zhang CY, Zhang Y, Yao ZH, Quan XH, Guo X, Wang CX. Tanshinone IIA attenuates high glucose induced human VSMC proliferation and migration through miR-21-5p-mediated tropomyosin 1 downregulation. Arch Biochem Biophys. 2019;677:108154.
44. Han H, Zhan Z, Xu L, Song Z. TMEFF2 inhibits pancreatic cancer cells proliferation, migration, and invasion by suppressing phosphorylation of the MAPK signaling pathway. Oncotargets Ther. 2019;12:11371–82.
45. Won KJ, Lee KP, Baek S, Cui L, Kwone MH, Jung SH, Ryu YK, Hong JM, Cho EA, Shin HS, Kim B. Desalted Sarcornia europaea extract attenuates vascular neo-intima formation by inhibiting the MAPK pathway-mediated migration and proliferation in vascular smooth muscle cells. Biomed Pharmacother. 2017;94:430–8.
46. Cattaruzza M, Schaffer K, Hecker M. Cytokine-induced down-regulation of zmf1/splcing factor-1 promotes smooth muscle cell proliferation. J Biol Chem. 2002;277:6582–9.
47. Monahan TS, Andersen ND, Martin MC, Malek JY, Shikhkhaned GV, Padrhan L, Ferran C, LoGerfo FW. MARCKS silencing differentially affects human vascular smooth muscle and endothelial cell phenotypes to inhibit neointimal hyperplasia in saphenous vein. FASEB J. 2009;23:557–64.
51. Sun L, Lin P, Chen Y, Yu H, Ren S, Wang J, Zhao L, Du G. miR-182-3p/Myadm contribute to pulmonary artery hypertension vascular remodeling via a KLF4/p21-dependent mechanism. Theranostics. 2020;10:5581–99.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.